GRAIL (NASDAQ:GRAL – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
Volatility and Risk
GRAIL has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.
Earnings & Valuation
This table compares GRAIL and Kymera Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GRAIL | $147.17 million | 40.23 | -$408.35 million | ($9.75) | -13.59 |
| Kymera Therapeutics | $39.21 million | 234.88 | -$311.35 million | ($3.24) | -34.19 |
Kymera Therapeutics has lower revenue, but higher earnings than GRAIL. Kymera Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares GRAIL and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRAIL | -236.95% | -15.88% | -14.02% |
| Kymera Therapeutics | -285.33% | -21.22% | -19.21% |
Analyst Ratings
This is a breakdown of current ratings and target prices for GRAIL and Kymera Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRAIL | 1 | 6 | 5 | 0 | 2.33 |
| Kymera Therapeutics | 1 | 2 | 23 | 1 | 2.89 |
GRAIL presently has a consensus price target of $119.80, suggesting a potential downside of 9.62%. Kymera Therapeutics has a consensus price target of $134.68, suggesting a potential upside of 21.60%. Given Kymera Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than GRAIL.
Summary
Kymera Therapeutics beats GRAIL on 7 of the 13 factors compared between the two stocks.
About GRAIL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
